DE1770324C3 - Polynicotinic acid esters of flavonolones, processes for their preparation and therapeutic compositions containing such compounds - Google Patents
Polynicotinic acid esters of flavonolones, processes for their preparation and therapeutic compositions containing such compoundsInfo
- Publication number
- DE1770324C3 DE1770324C3 DE19681770324 DE1770324A DE1770324C3 DE 1770324 C3 DE1770324 C3 DE 1770324C3 DE 19681770324 DE19681770324 DE 19681770324 DE 1770324 A DE1770324 A DE 1770324A DE 1770324 C3 DE1770324 C3 DE 1770324C3
- Authority
- DE
- Germany
- Prior art keywords
- compounds
- polynicotinic
- preparation
- acid esters
- mol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 title claims description 14
- 239000000203 mixture Substances 0.000 title claims description 10
- 238000000034 method Methods 0.000 title claims description 8
- 239000002253 acid Substances 0.000 title claims description 3
- 150000002148 esters Chemical class 0.000 title claims description 3
- 238000002360 preparation method Methods 0.000 title claims description 3
- 230000001225 therapeutic Effects 0.000 title claims 3
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 claims description 13
- 229930003935 flavonoids Natural products 0.000 claims description 7
- -1 nicotinoyl groups Chemical group 0.000 claims description 7
- 150000002215 flavonoids Chemical class 0.000 claims description 6
- 235000021285 flavonoid Nutrition 0.000 claims description 5
- 230000000875 corresponding Effects 0.000 claims description 2
- 235000017173 flavonoids Nutrition 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 16
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 15
- 229940025878 Hesperidin Drugs 0.000 description 13
- QUQPHWDTPGMPEX-YEDPJISVSA-N Hesperidin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C[C@@H](c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 QUQPHWDTPGMPEX-YEDPJISVSA-N 0.000 description 13
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 13
- 229940107161 Cholesterol Drugs 0.000 description 12
- 229960001285 Quercetin Drugs 0.000 description 12
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 12
- 235000012000 cholesterol Nutrition 0.000 description 12
- 229930002344 quercetin Natural products 0.000 description 12
- 235000005875 quercetin Nutrition 0.000 description 12
- FTVWIRXFELQLPI-ZDUSSCGKSA-N Naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 7
- 235000001968 nicotinic acid Nutrition 0.000 description 6
- 239000011664 nicotinic acid Substances 0.000 description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 235000007625 naringenin Nutrition 0.000 description 4
- 229940117954 naringenin Drugs 0.000 description 4
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 4
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 3
- DFPMSGMNTNDNHN-OHXUDFEXSA-N Naringin Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1Oc1cc(O)c2C(=O)C[C@@H](c3ccc(O)cc3)Oc2c1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 DFPMSGMNTNDNHN-OHXUDFEXSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229940081967 Rutin Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229940052490 naringin Drugs 0.000 description 3
- 229930002876 rutin Natural products 0.000 description 3
- 235000005493 rutin Nutrition 0.000 description 3
- 229960004555 rutoside Drugs 0.000 description 3
- DQFBYFPFKXHELB-UHFFFAOYSA-N 1,3-diphenylprop-2-en-1-one Chemical compound C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 2
- AIONOLUJZLIMTK-AWEZNQCLSA-N Hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 2
- 208000009576 Hypercholesterolemia Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 210000002381 Plasma Anatomy 0.000 description 2
- 235000005513 chalcones Nutrition 0.000 description 2
- 229930016212 chalcones Natural products 0.000 description 2
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 1
- FTVWIRXFELQLPI-UHFFFAOYSA-N NARINGENIN Chemical compound C1=CC(O)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-M chloride;hydrochloride Chemical compound Cl.[Cl-] IXCSERBJSXMMFS-UHFFFAOYSA-M 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Description
Gegenstand der Erfindung sind Polynicotinsäureester von Flavonoiden, die 2 bis 9 Nicotinoylgruppen enthalten. Die höchstmögliche Anzahl von Nicotinoylgruppen ist durch die Anzahl der freien Hydroxygruppen des jeweiligen Flavonoids begicnzt.The invention relates to polynicotinic acid esters of flavonoids containing 2 to 9 nicotinoyl groups contain. The highest possible number of nicotinoyl groups is determined by the number of free Hydroxy groups of the respective flavonoid limited.
Die erfindungsgemäße Herstellung dieser Verbindungen besteht darin, daß man in an sich bekannter Weise Nicotinsäurechlorid-hydrochlorid und ein entsprechendes Flavonoid im gewünschten stöchiometrischen Verhältnis umsetzt.The preparation according to the invention of these compounds consists in that one is known per se Way nicotinic acid chloride hydrochloride and a corresponding flavonoid in the desired stoichiometric Ratio implements.
So löst man z. B. Nicotinoylchlorid-hydrochlorid in Pyridin oder in einer Mischung aus Pyridin und Chloroform auf und gibt das Flavonoid, ebenfalls in Pyridin gelöst, zu der Lösung hinzu. Zur Gewinnung der erfindungsgemäßen Verbindungen mit dem hochsten Substitutionsgrad an Nicotinoylgruppen verwendet man einen großen stöchiometrischen Überschuß an Nicotinoylchlorid-hydrochlorid, während man zur Gewinnung von Verbindungen, die nur teilweise durch Nicotinoylgruppen substituiert sind, einen geringen Überschuß von etwa 10%, bezogen auf die gewünschten stöchiometrischen Mengenverhältnisse, verwendet.How to solve z. B. nicotinoyl chloride hydrochloride in pyridine or in a mixture of pyridine and Chloroform and gives the flavonoid, also dissolved in pyridine, to the solution. For extraction of the compounds according to the invention with the highest degree of substitution of nicotinoyl groups are used one a large stoichiometric excess of nicotinoyl chloride hydrochloride, while one for Obtaining compounds that are only partially substituted by nicotinoyl groups, a low Excess of about 10%, based on the desired stoichiometric proportions, used.
Die erfindungsgemäßen Verbindungen senken die Cholesterinmenge im Blut, ohne eine merkliche peripherische Gefäßerweiterung zu verursachen.The compounds according to the invention lower the amount of cholesterol in the blood without any noticeable causing peripheral vasodilation.
Die Überlegenheit der erfindungsgemäßen Verbindungen gegenüber dem aus der FR-PS 3161M bekannten Quercetin-mononicotinat geht aus den nachfolgenden Angaben hervor.The superiority of the compounds according to the invention over that known from FR-PS 3161M Quercetin mononicotinate can be found in the following information.
Die Wirksamkeit von 3 Nicotinsäurederivaten bei der Behandlung der Triglyceridämie wurde untersucht. The effectiveness of 3 nicotinic acid derivatives in the treatment of triglyceridemia was investigated.
1. Quercetin-mononicotinat, FR-PS 3161M,1. Quercetin mononicotinate, FR-PS 3161M,
2. Naringenin-nonanicotinat (F. 215° C),2. Naringenin nonanicotinate (m.p. 215 ° C),
3. Hesperidin-octanicotinat (F. 1520C).3. Hesperidin octanicotinate (m.p. 152 0 C).
Als Versuchstiere dienten Kaninchen, deren mittleres Gewicht 1,5 kg betrug. Die Kaninchen wurden in 5 Lose zu je 10 Tieren eingeteilt. Den Tieren des ersten Loses wurde keine Verbindung verabreicht; den Tieren der 4 übrigen Lose wurden 15 Tage iang durch eine Sonde 1 g Cholesterin je Tag und je Tier verabreicht, d. h., es wurde bei den Tieren eine Hypercholesterinämie erzeugt. Das erste dieser 4 Lose diente als Standard für die Hypercholesterinämie, die 3 übrigen Lose erhielten zusätzlich täglich durch eine Sonde, und zwar 30 Tage, die Verbindunp (1), Quercetin-mononicotinat, in einer Dosis von i,15g/kg und Tag, (2), Naringenin-nonanicotinat, in einer Dosis von 0,5 g/kg und Tag bzw. (3), Hesperidinoctanicotinat, in einer Dosis von ebenfalls 0,5 g/kg Nachdem zunächst die Werte von 0,5 g/kg festgelegt worden sind, kann die Dosis an Quercetinmononicotinat, welche dieselbe Nicotinsäuremenge beisteuert, leicht errechnet werden. Sie liegt in der Nähe von 1,15 g/kg und Tag. Die Nicotinsäuredosis in den beiden Verbindungen, welche für die Untersuchungen herangezogen werden, liegt größenordnunpsweise in der Nähe von 69%.Rabbits with an average weight of 1.5 kg were used as test animals. The rabbits were divided into 5 lots of 10 animals each. No compound was administered to the animals of the first lot; The animals of the 4 remaining lots were given 1 g of cholesterol per day and per animal for 15 days by means of a probe administered, d. that is, the animals became hypercholesterolemia generated. The first of these 4 lots served as the standard for the hypercholesterolemia that 3 other lots were additionally given the connection (1) daily through a probe for 30 days, Quercetin mononicotinate, in a dose of 1.15g / kg and day, (2), naringenin nonanicotinate, in one Dose of 0.5 g / kg and day or (3), hesperidinoctanicotinate, also in a dose of 0.5 g / kg After the values of 0.5 g / kg have been established, the dose of quercetin mononicotinate, which contributes the same amount of nicotinic acid can easily be calculated. It lies in the Close to 1.15 g / kg and day. The dose of nicotinic acid in the two compounds required for the examinations are used, is on the order of magnitude in the vicinity of 69%.
Die Bestimmung des Triglyceridgehaltes, ausgedrückt in g %o ml Plasma, wurde am 1., 15. und 30. Versuchstag in jedem Los durchgeführt.The determination of the triglyceride content, expressed in g% o ml plasma, was carried out on the 1st, 15th and 30. Test day carried out in each lot.
Die in der nachfolgenden Tabelle aufgezeichneten Ergebnisse zeigen, daß die Verbindung (1) zwar wirksam ist, aber von den Verbindungen (2) und (3) an Wirksamkeit wesentlich übertrofien wird.The results recorded in the table below show that compound (1) was is effective, but is significantly surpassed in effectiveness by compounds (2) and (3).
Trielyceride [g %o ml Plasma] bei Kaninchen, die, wie in der linken Spalte angegeben, behandelt wurden (die Cholesteringabe endete am 15. Tage)Trielycerides [g% o ml plasma] in rabbits treated as indicated in the left column (the cholesterol administration ended on the 15th day)
LoseLots
Vers. Nr.Verse. No.
Beginn 15 Tage 30 Tage Start 15 days 30 days
In einer weiteren Versuchsreihe wurden drei weitere erfindungsgemäße Verbindungen in gleicher Weise untersucht.In a further series of tests, three further compounds according to the invention were used in the same way Way investigated.
Nr.Verse.
No.
10 Versuchstiere,
die τώχ. 0,5 g/kg
Methylchalconhesperidin-nona-
nicotinat je Tag
behandelt worden
sind und denen
Cholesterin
gegeben worden ist10 laboratory animals,
the τώχ. 0.5 g / kg
Methylchalconesperidin-nona-
nicotinate per day
been treated
are and those
cholesterol
has been given
10 Versuchstiere,
die mit 0,5 g/kg
Rutin-nonanicoünat je Tag behandelt worden sind
und denen
Cholesterin
gegeben worden ist10 laboratory animals,
those with 0.5 g / kg
Rutin nonanicounate have been treated each day
and those
cholesterol
has been given
150
151
152
153
154
155
156
157
158
159150
151
152
153
154
155
156
157
158
159
Mittel:Medium:
160
161
162
163
164
165
166
167
168
169160
161
162
163
164
165
166
167
168
169
Mittel:Medium:
0,633 0,583 0,371 0,436 0,744 0,404 0,937 0,502 0,345 0,3130.633 0.583 0.371 0.436 0.744 0.404 0.937 0.502 0.345 0.313
0,5310.531
0,324 0,785 0,684 0,861 0,917 0,453 0,587 1,042 0,421 0,3720.324 0.785 0.684 0.861 0.917 0.453 0.587 1.042 0.421 0.372
0,6440.644
2,422 3,084 1,355 2,780 1,772 2,341 1,583 1,325 3,533 2,0342.422 3.084 1.355 2.780 1.772 2.341 1.583 1.325 3.533 2.034
2,2222.222
2,777 3,227 1,758 2,111 1,042 1,039 2,374 1,291 2,025 1,3162.777 3.227 1.758 2.111 1.042 1.039 2.374 1.291 2.025 1.316
1,8961,896
0,593 0,659 0,975 1,438 0,924 0,435 1,012 0,853 1,158 0,7850.593 0.659 0.975 1.438 0.924 0.435 1.012 0.853 1.158 0.785
0,8830.883
0,631 1,369 1,167 0,752 0,741 1,019 0,884 1,493 1,904 0,8110.631 1.369 1.167 0.752 0.741 1.019 0.884 1.493 1.904 0.811
1,0771.077
Die Toxizität der erfindungsgemäßen Verbindungen wurde an Mäusen im Experiment geprüft. Bei Dosismengeu von 10 g/kg wurde keine Sterblichkeit beobachtet.The toxicity of the compounds according to the invention was tested on mice in an experiment. at At a dose level of 10 g / kg, no mortality was observed.
Beispiel 1 Hesperidin-octanicotinatExample 1 hesperidin octanicotinate
213,8g (1,2 Mol) Nicotinoylchlorid-hydrochlorid werden in einer Mischung aus 235 ml Pyridin und213.8 g (1.2 moles) nicotinoyl chloride hydrochloride are in a mixture of 235 ml of pyridine and
♦o 600 ml Chloroform gelöst und 2 Stunden lang unter Rückfluß erhitzt. Die Mischung wird dann abgekühlt und tropfenweise unter Bewegung bei einer Temperatur von 10° C mit 0,1 MoI (61 g) Hesperidin, das in 500 ml Pyridin gelöst ist, versetzt♦ o 600 ml of chloroform dissolved and taken for 2 hours Heated to reflux. The mixture is then cooled and added dropwise with agitation at a temperature of 10 ° C with 0.1 mol (61 g) hesperidin, the is dissolved in 500 ml of pyridine, added
Man hält die Mischung 6 Stunden lang weiter in Bewegung und läßt sie dann drei Tage lang stehen. Das Pyridin und das Chloroform werden unter vermindertem Druck entfernt, der Rückstand wird mit Wasser verrieben, dann wird der ungelöste Anteil mit einer 10°/oigen Lösung von Natriumbicarbonat und darauf so lange mit Wasser gewaschen, bis ein pH-Wert von etwa 7 und vollständige Abwesenheit von Cl"-Ionen erreicht sind.The mixture is kept moving for 6 hours and then allowed to stand for three days. The pyridine and chloroform are removed under reduced pressure, the residue is washed with Triturated water, then the undissolved portion with a 10% solution of sodium bicarbonate and then washed with water until a pH of about 7 and complete absence of Cl "ions are reached.
Das getrocknete Produkt wiegt 122 g; die Stickstoffbestimmung durch nichtwäßrige Protometrie und Analyse zeigt, daß es Hesperidin-octanicotinat ist; F. 152° C.The dried product weighs 122 g; the nitrogen determination shows by non-aqueous protometry and analysis that it is hesperidin octanicotinate is; 152 ° C.
Beispiel 2 Hesperidin-hexanicotinatExample 2 hesperidin hexanicotinate
Man geht wie in Beispiel 1 vor unter Verwendung von 61 g (0,1 Mol) Hesperidin and 116 g (0,65 Mol) Nicotinoylchlorid-hydrochlorid, das in 320 ml Chloroform und 130 ml Pyridin gelöst ist. Man erhitzt 3 Stunden unter Rückfluß und erhält Hesperidin-hexanicotinat; F. 164° C.The procedure is as in Example 1, using 61 g (0.1 mol) of hesperidin and 116 g (0.65 mol) nicotinoyl chloride hydrochloride dissolved in 320 ml of chloroform and 130 ml of pyridine. The mixture is refluxed for 3 hours and hesperidin hexanicotinate is obtained; 164 ° C.
Beispiel 3
Hesperidin-tetranicotinatExample 3
Hesperidin tetranicotinate
Mim geht wie in Beispiel 2 vor und verwendet 61 g (0,1 Mol) Hesperidiu, aber 79 g (0,44 Mol) Nicotinoylchlorid-hydrochlorid. Man erhält Hesperidintetranicotinat; F. 177° C.Mim proceeds and uses as in Example 2 61 g (0.1 mol) of Hesperidiu, but 79 g (0.44 mol) of nicotinoyl chloride hydrochloride. Hesperidin tetranicotinate is obtained; 177 ° C.
Naringin-octanicotinatNaringin octanicotinate
Man geht wie in Beispiel 1 vor, verwendet aber 61,6 g (0,1 Mol) Naringin-dihydrat und 213,8 g (1,2 Mol) Nicotinoylchlorid-hydrochlorid. Man erhält Naringin-octanicotinat; F. 155° C.The procedure is as in Example 1, except that 61.6 g (0.1 mol) of naringin dihydrate and 213.8 g are used (1.2 moles) nicotinoyl chloride hydrochloride. You get Naringin octanicotinate; 155 ° C.
Beispiel 5
Methyl-chalcon-hesperidin-nonanicotinatExample 5
Methyl chalcone hesperidin nonanicotinate
Man geht wie in Beispiel 1 vor und verwendet 61 g (0,1 Mol) Methyl-chalcon-hesperidin und 268 g (1,5 Mol) Nicotinoylchlorid-hydrochlorid. Man erhält Methyl-chalcon-hesperidin-nonanicotinat; F. 125° C.The procedure is as in Example 1 and 61 g (0.1 mol) of methyl chalcone-hesperidin and 268 g are used (1.5 moles) nicotinoyl chloride hydrochloride. Methyl chalcone hesperidin nonanicotinate is obtained; F. 125 ° C.
Rutin-nonanicotinatRutin nonanicotinate
Man geht wie in Beispiel 1 vor und verwendet 66,5 g (0.1 Mol) Rutin-trihydrat und 268 g (1,5 Mol) Nicotinoylchlorid-hydrochlorid. Man erhält Rutinnonanicotinat; F.165° C.Proceed as in Example 1 and use 66.5 g (0.1 mol) of rutin trihydrate and 268 g (1.5 mol) Nicotinoyl chloride hydrochloride. Rutin nonanicotinate is obtained; 165 ° C.
Die nachfolgenden Beispiele betreffen die Herstellung von aglykonischen Flavonoid-nicotinaten. Die Synthesereaktionen können daher in der Hitze durchgeführt werden.The following examples relate to the production of aglyconic flavonoid nicotinates. The synthesis reactions can therefore be carried out in the heat.
Beispiel 7
Hesperidin-trinicotinatExample 7
Hesperidin trinicotinate
89 g (0,5 Mol) Nicotmoylchlorid-hydrochlorid werden 3 Stunden in 100 ml wasserfreiem Pyridin unter Sieden erhitzt. Nach dem Abkühlen auf etwa 30° C werden 30 g (0,1 Mol) Hesperetin, in 350 ml Pyridin gelöst, zugesetzt. Danach wird die Mischung 2'Stunden lang unter Rückfluß gehalten. Man läßt die Mischung sich abkühlen, gießt sie in Eiswasser, bewegt und läßt den Niederschlag sich absetzen. Er wird dann abgetrennt und, wie in Beispiel 1 angegeben, behandelt. Das so erhaltene Hesperedin-trinicotinat wird aus Methanol umkristallisiert; F. 161GC.89 g (0.5 mol) of nicotmoyl chloride hydrochloride are heated to boiling in 100 ml of anhydrous pyridine for 3 hours. After cooling to about 30 ° C., 30 g (0.1 mol) of hesperetin, dissolved in 350 ml of pyridine, are added. The mixture is then refluxed for 2 hours. The mixture is allowed to cool, poured into ice water, agitated and the precipitate is allowed to settle. It is then separated off and treated as indicated in Example 1. The hesperedin trinicotinate obtained in this way is recrystallized from methanol; F. 161 G C.
Beispiel 8
Narin genin-trinicotinatExample 8
Narin genin-trinicotinate
Man arbeitet wie in Beispiel 7 und verwendet 89 g (0,5 Mol) Nicotinoylchlorid-hydrochlorid und 27,2 g (0,1 Mol) Naringenin. Man erhält Naringenin-trinicotinat, das aus Methanol umkristallisiert wird; F.140° C.The procedure is as in Example 7 and 89 g (0.5 mol) of nicotinoyl chloride hydrochloride and 27.2 g are used (0.1 mole) naringenin. Naringenine trinicotinate is obtained, which is recrystallized from methanol; F. 140 ° C.
Quercetin-trinicotinatQuercetin trinicotinate
Man arbeitet wie in Beispiel 7 und verwendet 59 g (0,33 Mol) Nicotinoylchlorid-hydrochlorid und 33,8 g (0.1 Mol) Quercetin. Man erhält Quercetin-trinicotinat; F. 2050C.The procedure is as in Example 7 and 59 g (0.33 mol) of nicotinoyl chloride hydrochloride and 33.8 g (0.1 mol) of quercetin are used. Quercetin trinicotinate is obtained; F. 205 0 C.
Beispiel 10
Quercetin-pentanicotinatExample 10
Quercetin pentanicotinate
Man arbeitet wie in Beispiel 9 und verwendet 178,2 g (1 Mol) Nicotinoylchlorid-hydrochlorid und 33,8 g (0,1 Mol) Quercetin. Man erhitzt 5 Stunden unter Rückfluß und erhält Quercetin-pentanicotinat; F.184°C.The procedure is as in Example 9 and used 178.2 g (1 mol) of nicotinoyl chloride hydrochloride and 33.8 g (0.1 mole) quercetin. The mixture is refluxed for 5 hours and quercetin pentanicotinate is obtained; M.p. 184 ° C.
Claims (3)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2107867 | 1967-05-05 | ||
GB21078/67A GB1179019A (en) | 1967-05-23 | 1967-05-23 | Polynicotinic Esters of Flavonoids |
Publications (3)
Publication Number | Publication Date |
---|---|
DE1770324A1 DE1770324A1 (en) | 1972-04-20 |
DE1770324B2 DE1770324B2 (en) | 1976-07-22 |
DE1770324C3 true DE1770324C3 (en) | 1977-03-24 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE1445154B2 (en) | 1,4-DIHYDRO-1,8-NAPHTHYRIDE DERIVATIVES AND A METHOD FOR THEIR PRODUCTION | |
DE19824983A1 (en) | New L-ascorbic acid derivative | |
DE2141634C3 (en) | New isoindoline derivatives, their manufacture and compositions containing them | |
DE3009071C2 (en) | 2-isopropylamino-hydroxypyrimidine compounds, processes for their preparation and pharmaceuticals containing these compounds | |
DE1179556B (en) | PROCESS FOR THE PREPARATION OF FREE OR ACYLATED N- (4-DIETYLAMINOBUTYL) -SALICYCLIC ACID | |
DE1793646C3 (en) | Glyoxyldithiosemicarbazone excretion from 1518228 | |
CH644263A5 (en) | PREPARATIONS USED FOR COSMETIC PURPOSES AND METHOD FOR PRODUCING THE ACTIVE SUBSTANCES OF THESE PREPARATIONS. | |
DE2265138C3 (en) | Vincamic acid benzyl ester, its salts with acids, a process for their preparation and pharmaceutical agents | |
DE2627146A1 (en) | ADRIAMYCINESTERS AND METHOD FOR PRODUCING THEREOF | |
DE2707095C3 (en) | Isopropylaminopyrimidine orthophosphate | |
DE1770324C3 (en) | Polynicotinic acid esters of flavonolones, processes for their preparation and therapeutic compositions containing such compounds | |
DE2114607A1 (en) | New quinazolinone derivatives and their method of manufacture | |
DE2065312C3 (en) | Aminoethanesulfonyl derivatives and processes for their preparation | |
AT391699B (en) | METHOD FOR PRODUCING NEW 4-CHLORO SUBSTITUTED FURO- (3,4-C) -PYRIDINE DERIVATIVES | |
DE1770324B2 (en) | POLYNICOTIC ACID ESTERS OF FLAVONOIDS, PROCESS FOR THEIR PRODUCTION AND THERAPEUTIC COMPOSITIONS CONTAINING SUCH COMPOUNDS | |
DE2557033C2 (en) | Acyl derivatives of 1,2-5,6-dianhydro-dulcite, processes for their preparation and anticarcinogenic agents containing these compounds | |
DE2000030B2 (en) | 3 alkoxy and 3 phenoxy 2 (diphenyl hydroxy) methyl propylamine and medicinal products containing them | |
DE2320945A1 (en) | NEW ESTERS OF ACETYL SALICYLIC ACID | |
DE2843136C3 (en) | 6-O-mono- and 1,6-O-di-acylated 2- [3- (2-chloroethyl) -3-nitroscureido] -2-deoxy-D-glucopyranoses and mixtures of 1,3,6-O- Tri and 1,4,6-O-tri-acylated 2- [3- (2-chloroethyl) -3-nitrosoureido] -2-deoxy-D-glucopyranoses | |
CH624112A5 (en) | ||
DE2264638C2 (en) | 5'-acetyl-2,2'-cyclocytidine derivatives | |
DE1936274C3 (en) | Biguanide nicotinates, processes for their preparation and medicinal products containing them | |
DE2322073A1 (en) | NEW AMINO DERIVATIVES OF PYRIDOPYRIDAZINE CARBONIC ACID ESTERS AND CARBONIC ACIDS WITH THEIR SALT | |
DE2361488C3 (en) | Use of tri-n-propyl acetic acid derivatives | |
DE1795125C (en) | Quinoline derivatives, a process for their preparation and pharmaceuticals |